UNLIMITED TURBO SHORT - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 03:21:10 2024-07-17 am EDT | ||
| 2.96 EUR | -0.34% |
|
| Current month | -1.98% | ||
| 1 month | -2.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 2.96 | -0.34% |
| 24-07-16 | 2.97 | -2.94% |
| 24-07-15 | 3.06 | +1.66% |
| 24-07-12 | 3.01 | 0.00% |
| 24-07-11 | 3.01 | +0.67% |
Delayed Quote Deutsche Boerse AG
Last update July 17, 2024 at 03:21 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PE6V06 |
| ISIN | DE000PE6V068 |
| Date issued | 2022-12-19 |
| Strike | 73.23 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.25 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.15 € |
|---|---|
| Lowest since issue | 0.058 € |
| Spread | 0.01 € |
| Spread % | 0.34% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2
USD
Average target price
52.69
USD
Spread / Average Target
+27.90%
- Stock Market
- Certificates
- Certificat
